医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories Limited to Present at the 36th Annual J.P. Morgan Healthcare Conference

2018年01月06日 PM03:39
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd (BSE: 500124)(NSE: DRREDDY)(NYSE: RDY) announced that the Company will be presenting at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Alok Sonig, Executive Vice President and Head, North America will present on Tuesday, January 9, 2018 at 2 p.m. (PST) [3:30 a.m. IST on January 10, 2018].

Presentation material will be available on the Company’s website www.drreddys.com.

Biographical Information:

Alok Sonig is Executive Vice President (Global) and Head of the North America region for Dr. Reddy’s Laboratories. He is a member of the Global Management Council for the corporation. Alok joined Dr. Reddy’s in June 2012, running both the India-region in addition to Global Business Development. During his tenure, the India business delivered industry-leading growth and saw successful acquisitions and integration of strategically important businesses. Prior to joining Dr. Reddy’s, Sonig spent nearly 15 years at Bristol-Myers Squibb, where he held several leadership positions in general management, country leadership, global strategy and marketing, mostly based in the U.S. His last role was Vice President of Strategy in Princeton, New Jersey. Before joining Bristol-Myers Squibb, Sonig was based in Washington, D.C., where he spent several years as a management consultant working in various industries on strategy and innovation assignments, including health care, technology and telecommunications. Currently, he is a board member of the Association for Accessible Medicine. He holds a Bachelors of Engineering degree from Punjab Engineering College in India, as well as a Masters in Business Administration from American University in Washington, D.C. Sonig is married with two daughters and lives in the Princeton, New Jersey, area.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180105005895/en/

CONTACT

DR. REDDY’S LABORATORIES LTD.
INVESTOR RELATIONS
SAUNAK
SAVLA, +91-40-49002135
saunaks@drreddys.com
or
MEDIA
RELATIONS

CALVIN PRINTER, +91-40-49002121)
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • サンフランシスコで5月11日に開催される賞金100万ドルのコンテスト「スタートアップワールドカップ」に世界トップの技術リーダーが参加
  • Certara社がマーケットアクセス、医療経済・アウトカム研究(HEOR)およびリアルワールドエビデンスソリューション分野のリーダーであるAnalytica Laser社を買収
  • 全球顶尖高科技领军人物将于5月11日在旧金山举行的百万美元创业世界杯总决赛上发言
  • Kansai Paint Group Announces First Ever Anti-Mosquito Paint Approved By the EPA
  • Shionogi to Present New Data at 2018 European Congress of Clinical Microbiology and Infectious Diseases